| Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection (NCT07536282) | Newish Biotech (Wuxi) Co., Ltd. | 2026-10-01 |
| Oral and Sublingual Ketamine (NCT07683988) | Western University, Canada | 2026-10-01 |
| Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor (NCT07041203) | Kristina Simonyan | 2026-10-01 |
| CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma (NCT07575893) | New York Medical College | 2026-10-01 |
| A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus (NCT07606521) | Polpharma Biologics International AG | 2026-10-01 |
| Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients (NCT06615752) | Charles Drew University of Medicine and Science | 2026-10-01 |
| Amnion Membrane Powder Mohs Study (NCT07680023) | Wake Forest University Health Sciences | 2026-10-01 |
| A Study of DS-3939a in Participants With Solid Tumors (NCT07739966) | Daiichi Sankyo | 2026-10-01 |
| Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers (NCT07553390) | M.D. Anderson Cancer Center | 2026-10-01 |
| Study of STLX-2012 in Healthy Volunteers (NCT07231744) | Stelexis BioSciences | 2026-10-01 |
| Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma (NCT07719127) | Case Comprehensive Cancer Center | 2026-10-01 |
| Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer (NCT07700420) | University of Texas Southwestern Medical Center | 2026-10-01 |
| Placental Cells for Diabetic Foot Ulcers (NCT07686094) | Wake Forest University Health Sciences | 2026-10-01 |
| Evaluate Preliminary Anti-tumor Activity of Elraglusib in Adult Participants With Advanced Solid Tumors (NCT07714395) | Actuate Therapeutics Inc. | 2026-10-01 |
| A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease (NCT07431294) | Bayer | 2026-10-01 |
| A Multimodal Imaging Study of Dopamine in Early Psychosis (NCT06977308) | New York State Psychiatric Institute | 2026-10-01 |
| Pre-emptive Anakinra for Cytokine Event Reduction (NCT06703216) | Kevin McNerney | 2026-10-01 |
| Breast-milk Enema Administration to Stimulate Passage of Meconium (NCT07661992) | Wake Forest University Health Sciences | 2026-10-01 |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT07221032) | Medical College of Wisconsin | 2026-10-01 |
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study (NCT06743555) | Centre hospitalier de l'Université de Montréal (CHUM) | 2026-10-01 |
| Testing a Peer-led Trauma-focused Intervention for Significant Others of Those With BPD (NCT06135090) | York University | 2026-10-01 |
| Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora (NCT03463239) | Wake Forest University Health Sciences | 2026-10-01 |
| First-in-human Study of UX016 in GNEM (NCT07511556) | Ultragenyx Pharmaceutical Inc | 2026-10-01 |
| Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) (NCT07530263) | Radboud University Medical Center | 2026-10-01 |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma (NCT07667868) | BrightPath Biotherapeutics Co., Ltd. | 2026-10-01 |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (NCT06982222) | National Cancer Institute (NCI) | 2026-10-01 |
| Safely Quenching Complement in Stroke Survivors (NCT07495722) | Columbia University | 2026-10-01 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) (NCT06792500) | George Washington University | 2026-10-01 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (NCT07175415) | Princess Maxima Center for Pediatric Oncology | 2026-10-01 |
| CD19-Directed CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (NCT07659704) | University of Sao Paulo | 2026-10-01 |
| Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics (NCT07758231) | University of Wisconsin, Madison | 2026-10-01 |
| Carbon Monoxide Hyperbaric Oxygen With Steroid Therapy (NCT06574048) | University of Nebraska | 2026-10-01 |
| Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Interstitial Lung Disease (NCT06534528) | Shanghai Life Science & Technology | 2026-10-01 |
| Tolerability of Enteral NAC in Infants (NCT06260566) | Sanjiv Harpavat | 2026-10-01 |
| Open Label Clinical Trial of Intravenous Crotoxin Part 3 (NCT01481532) | Celtic Biotech Ltd | 2026-10-01 |
| A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes (NCT07765511) | Eli Lilly and Company | 2026-10-01 |
| Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia (NCT07766850) | Christer C Nilsson | 2026-10-01 |
| Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (NCT06675123) | City of Hope Medical Center | 2026-10-01 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease (NCT07729995) | Luminary Therapeutics | 2026-10-01 |
| Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma (NCT07761286) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-09-30 |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease (NCT07709741) | University of Minnesota | 2026-09-30 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ONO-6414 Administered Orally in Healthy Adult Participants and Patients With Active Ulcerative Colitis (NCT07749768) | Ono Pharmaceutical Co., Ltd. | 2026-09-30 |
| A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata (NCT07762443) | Jiangsu vcare pharmaceutical technology co., LTD | 2026-09-30 |
| Evaluation of PAN-90806 Eye Drops in Healthy Subjects (NCT07764965) | Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | 2026-09-30 |
| Taurine Supplementation in Adolescents With Post-COVID Condition (NCT07682402) | University of Alberta | 2026-09-30 |
| Evaluating the Effects of Propionate and Butyrate Supplementation on the Intestinal Health of Healthy Volunteers (NCT07611370) | City of Hope Medical Center | 2026-09-30 |
| A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma (NCT07700212) | M.D. Anderson Cancer Center | 2026-09-30 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT07552558) | Washington University School of Medicine | 2026-09-30 |
| A Study of Amicidin-β Topical Solution for Patients With Surgical or Traumatic Wound Infections (NCT07379684) | Macro Biologics, Inc. | 2026-09-30 |
| A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC (NCT07725796) | UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd. | 2026-09-30 |
| A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression (NCT07686445) | Adlai Nortye Biopharma Co., Ltd. | 2026-09-23 |
| A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants (NCT07716241) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2026-09-22 |
| S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation (NCT07722312) | Servier | 2026-09-20 |
| Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation (NCT07753148) | Regeneron Pharmaceuticals | 2026-09-17 |
| Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis (NCT07756268) | Tongji Hospital | 2026-09-16 |
| Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy (NCT06065670) | University of California, San Francisco | 2026-09-15 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies (NCT07719348) | Servier | 2026-09-15 |
| Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer (NCT07765940) | RadAlliance Therapeutics, Inc | 2026-09-15 |
| Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients (NCT07568041) | Cenna Biosciences Inc. | 2026-09-15 |
| A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis (NCT07412704) | Bristol-Myers Squibb | 2026-09-15 |
| Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH) (NCT06696131) | Gaurav Gupta, MD | 2026-09-15 |
| A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body (NCT07649265) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2026-09-15 |
| A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies (NCT07628582) | The First Affiliated Hospital with Nanjing Medical University | 2026-09-15 |
| A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults (NCT06507904) | Pfizer | 2026-09-15 |
| Effects of Stimulant Medications in PTSD (NCT07664631) | University of Chicago | 2026-09-15 |
| A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies (NCT07569029) | National Institute of Allergy and Infectious Diseases (NIAID) | 2026-09-15 |
| Clinical Study of Non-invasive 40-Hz Audiovisual Stimulation Guided by Gamma EEG Monitoring for Promoting Perioperative Brain Function Recovery in Children (NCT07719465) | General Hospital of Ningxia Medical University | 2026-09-15 |
| CBD for Breast Cancer Primary Tumors (NCT06148038) | Medical University of South Carolina | 2026-09-15 |
| A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008) (NCT07743151) | Merck Sharp & Dohme LLC | 2026-09-15 |
| Augmenting Cerebral Blood Flow in Acute Ischemic Stroke (NCT06911385) | University of Alberta | 2026-09-15 |
| Effects of Various Cannabis Strains on Perceptual, Subjective and Objective Use Outcomes (NCT07214155) | Johns Hopkins University | 2026-09-15 |
| A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab (NCT07619599) | City of Hope Medical Center | 2026-09-14 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (NCT07498465) | Children's Oncology Group | 2026-09-10 |
| A Study to Evaluate the Safety, Tolerability, PK and Preliminary Efficacy of HX15001 Combined With Etrasimod in Moderate-severe Ulcerative Colitis (NCT07768254) | Helixon Biotechnology (Suzhou) Co., Ltd | 2026-09-09 |
| Fentanyl Intranasal for Retinopathy of Prematurity Screening in Preterm Infants (NCT07112430) | Marsha Campbell-Yeo | 2026-09-09 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis (NCT07759167) | Regeneron Pharmaceuticals | 2026-09-09 |
| A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) (NCT07602855) | GlaxoSmithKline | 2026-09-08 |
| A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) (NCT07416552) | Hoffmann-La Roche | 2026-09-08 |
| Psilocybin for Treatment of OCD-2 (NCT06992999) | Francisco A Moreno | 2026-09-08 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma (NCT07619521) | National Cancer Institute (NCI) | 2026-09-08 |
| Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer (NCT07436858) | The Netherlands Cancer Institute | 2026-09-07 |
| Impact of Exogenous Ketones on Sleep Apnea (NCT06687655) | Johns Hopkins University | 2026-09-06 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations (NCT07746141) | BeOne Medicines | 2026-09-04 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of VG2025 Intravenous Injection in Subjects With Advanced Solid Tumors (NCT07682870) | Virogin Biotech Ltd. | 2026-09-04 |
| A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers (NCT07658482) | Zai Lab (Shanghai) Co., Ltd. | 2026-09-03 |
| Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment (NCT06888323) | National Cancer Institute (NCI) | 2026-09-03 |
| Safety of Topical Exosome-Containing Liquid in Healthy Volunteers (NCT07703969) | West Kazakhstan Marat Ospanov Medical University | 2026-09-01 |
| A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma (NCT07760454) | UCARsgen Biotech Limited | 2026-09-01 |
| A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD (NCT07076290) | Rise Therapeutics LLC | 2026-09-01 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (NCT07225439) | Paolo Caimi, MD | 2026-09-01 |
| A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity (NCT07768813) | Boehringer Ingelheim | 2026-09-01 |
| Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use (NCT07707986) | West Kazakhstan Marat Ospanov Medical University | 2026-09-01 |
| Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms (NCT07679334) | Roswell Park Cancer Institute | 2026-09-01 |
| A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity (NCT07747857) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-09-01 |
| Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus (NCT02664740) | Centre Hospitalier Universitaire de Nīmes | 2026-09-01 |
| Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects (NCT07738562) | Hadassah Medical Organization | 2026-09-01 |
| A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration (NCT07718165) | Abbisko Therapeutics Co, Ltd | 2026-09-01 |
| Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of QLS2319 in Healthy Subjects and Cancer Cachexia (NCT07735104) | Qilu Pharmaceutical Co., Ltd. | 2026-09-01 |
| Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy (NCT07762703) | BreakBio Corp | 2026-09-01 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation (NCT07678593) | Genfleet Therapeutics (Shanghai) Inc. | 2026-09-01 |